Primigravida with generalized myasthenia gravis leading to caesarean section delivery: a case report.

J Matern Fetal Neonatal MedSep 10, 2026 (epub)
Case ReportObstetrics & GynecologyNeurologyAnesthesiology

Alce Everdien, Andi Kurniadi, Adhi Pribadi et al.

✦ AI-curated · Sources linked

Case in brief

A 25-year-old primigravida with a history of ocular myasthenia gravis experienced progression to generalized myasthenia gravis during pregnancy. She presented for delivery at 37 weeks gestation, having been stable on pyridostigmine therapy. A planned cesarean section was performed under spinal anesthesia to reduce the risk of respiratory fatigue. Both mother and neonate had favorable outcomes, with no postpartum exacerbation.

Diagnostic / clinical pearl

Multidisciplinary coordination is essential in managing pregnant patients with myasthenia gravis to ensure safe delivery and minimize complications.

Why it matters

This case highlights the importance of respiratory assessment and disease stability in making delivery decisions for patients with myasthenia gravis.

Source

PubMed · PMID 42722510

Published in J Matern Fetal Neonatal Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.